[Effects of high dose glucose-insulin-potassium infusion on myocardial injury and serum sFas/ sFasL concentration in acute myocardial infarction].
OBJECTIVE
This study was designed to evaluate reperfusion therapy, co-administered with high dose glucose-insulin-potassium (GIK) treatment on serum soluble Fas/APO-1 (sFas) and Fas ligand (sFasL) concentration in Acute Myocardial Infarction (AMI) patients.


METHODS
Seventy-four patients with AMI underwent reperfusion therapy were randomized into GIK group (n = 35) receiving high-dose GIK for 24 hours or a vehicle group (n = 39). Thirty-four control subjects (NC) were also enrolled in the present study. Strepavidin-biotin ELISA was used to determine the serum sFas and sFasL concentration at baseline and different time point (24 h, 3 d, 7 d and 14 d) after reperfusion.


RESULTS
(1) The serum concentration of sFas and sFas-L ([sFas] and [sFas-L]) of AMI patients were significantly elevated at baseline as compared with NC (P < 0.01). (2) The [sFas] in GIK and non-GIK group decreased 24 h after reperfusion (P < 0.01 vs. baseline) and then increased during 3-7 d period (P < 0.01 vs. 24 h). (3) The GIK group demonstrated reduced [sFas] at 14 d (P < 0.01 vs. 7 d), with no concomitant changes in the non-GIK group. (4) The [sFasL] in the GIK and non-GIK group were no significant difference during 3-14 d period. CONCLUSION Owing to cardioprotective effects reported here and by others, a high-dose GIK infusion co-administered with the timely establishment of perfusion should be strongly considered as a treatment of choice for AMI.
Zhang
Lei
L
Department of Cardiology, Capital University Affiliating Beijing Chaoyang Hospital, Beijing 100020, China.
Zhang
Lin
L
Li
Yan-hui
YH
Chen
Mu-lei
ML
Zhang
Hai-yong
HY
Gao
Ming-ming
MM
D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D017209:Apoptosis / Q000187:drug effects; D003131:Combined Modality Therapy; D053222:Fas Ligand Protein; D005260:Female; D005947:Glucose / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000473:pathology / Q000628:therapy*; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control; D011188:Potassium / Q000008:administration & dosage / Q000627:therapeutic use; D048069:Tumor Necrosis Factors / Q000097:blood*; D019014:fas Receptor / Q000097:blood*
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D007328:Insulin; D008562:Membrane Glycoproteins; D048069:Tumor Necrosis Factors; D019014:fas Receptor; C030396:glucose-insulin-potassium cardioplegic solution; D005947:Glucose; D011188:Potassium